Summary & Overview
CPT 81441: Genomic Sequence Analysis Panel for Solid Organ Neoplasms
CPT code 81441 represents a genomic sequence analysis panel for solid organ neoplasms, focusing on DNA analysis of 5 to 50 genes. This code is significant in the national landscape as it supports precision medicine approaches in oncology, enabling clinicians to identify genetic mutations that may influence treatment decisions for various cancers. The procedure is categorized under Pathology and Laboratory services and is most commonly performed in independent laboratory settings.
Major national payers, including Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare, provide coverage for this code, reflecting its widespread clinical adoption and relevance. Readers will gain insights into payer coverage, clinical indications, and related coding practices, including common modifiers and associated taxonomies. The publication also highlights relevant ICD-10 diagnoses, such as malignant neoplasms of the lung, breast, colon, prostate, and pancreas, which are frequently linked to the use of this genomic panel.
Key benchmarks and policy updates are discussed, offering a comprehensive overview of how CPT code 81441 fits into current laboratory and pathology billing practices. The article also explores related CPT codes and the clinical context for genomic testing in oncology, providing readers with a clear understanding of the code's role in advancing cancer diagnostics and personalized care.
CPT Code Overview
CPT code 81441 is used for genomic sequence analysis panels targeting solid organ neoplasms, specifically DNA analysis involving 5 to 50 genes. This procedure falls under the Pathology and Laboratory service type and is typically performed in an Independent Laboratory setting (Place of Service 81). The test is designed to provide comprehensive genetic information that can inform diagnosis and treatment strategies for patients with solid organ tumors.
Clinical & Coding Specifications
Clinical Context
A patient diagnosed with a solid organ neoplasm, such as lung, breast, colon, prostate, or pancreatic cancer, is referred for advanced molecular testing. The treating oncologist requests a genomic sequence analysis panel to identify mutations in 5-50 genes relevant to the tumor. The specimen, typically a tissue biopsy, is sent to an independent laboratory (Place of Service 81) specializing in pathology and molecular diagnostics. The laboratory performs DNA analysis using CPT code 81441 to guide targeted therapy decisions and inform prognosis. Results are interpreted by a pathologist or molecular oncologist and reported back to the treating physician.
Coding Specifications
-
Modifiers:
- Modifier
26: Used when billing for the professional component, which includes interpretation and reporting of results by a qualified physician. - Modifier
TC: Used when billing for the technical component, which covers the laboratory's performance of the genomic sequencing procedure.
- Modifier
-
Provider Taxonomies:
| Taxonomy Code | Specialty Name |
|---|